```html

Waxing and Waning Migraines – A Comprehensive Medical Guide

Overview

Waxing and waning migraines refer to migraine attacks whose intensity, frequency, or associated symptoms fluctuate over time. A patient may experience periods of severe, frequent headaches (the “waxing” phase) followed by intervals of milder attacks or even headache‑free stretches (the “waning” phase). This pattern is common among people with chronic migraine, medication‑overuse headache, or hormonal migraine.

Who it affects: Migraine is one of the most prevalent neurological disorders worldwide. According to the World Health Organization, roughly 15 % of the global population experiences migraine at some point, with a higher prevalence in women (approximately 18 % of adult women vs. 6 % of adult men).<sup>[1] WHO, 2023</sup> The “waxing‑and‑waning” pattern is especially observed in:

• Individuals with chronic migraine (≥15 headache days per month for >3 months, of which ≥8 are migraine days).
• People who overuse acute headache medications.
• Women with menstrual or pregnancy‑related hormonal changes.

Symptoms

Migraine attacks are heterogeneous. When they wax and wane, the following features may change from one phase to another.

Core migraine features (present in most attacks)

• Pulsating or throbbing head pain – often unilateral, but can become bilateral during worsening phases.
• Moderate to severe intensity – typically rated 6–9 on a 0–10 pain scale.
• Aggravation by routine physical activity (climbing stairs, walking).
• Nausea and/or vomiting.
• Photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Symptoms that may wax or wane

• Aura – visual (flashing lights, zig‑zag lines), sensory (tingling), or speech disturbances that precede the headache. Aura may be present in 25–30 % of migraineurs, but can disappear during milder phases.
• Duration – classic migraine lasts 4–72 hours. In waxing periods, attacks may linger toward the upper limit; during waning, they may resolve within 4–6 hours.
• Neck pain or stiffness – becomes more prominent when attacks intensify.
• Fatigue and difficulty concentrating – often more marked after a severe episode.
• Allodynia – pain from normally non‑painful stimuli (e.g., wearing a hat). This tends to develop after repeated or prolonged attacks.

Causes and Risk Factors

migraine is a neurovascular disorder influenced by genetics, brain chemistry, and environmental triggers. The waxing‑and‑waning pattern usually reflects the interplay of several factors.

Underlying mechanisms

• Trigeminovascular activation – the trigeminal nerve releases calcitonin gene‑related peptide (CGRP), causing vasodilation and inflammation.
• Cortical spreading depression (CSD) – a wave of neuronal depolarization that underlies aura and may sensitize pain pathways.
• Central sensitization – repeated attacks lower the pain threshold, leading to more severe, longer‑lasting episodes.

Risk factors that promote waxing phases

• Frequent use of acute medications (e.g., triptans, NSAIDs) – can cause medication‑overuse headache, intensifying frequency.
• Hormonal fluctuations – estrogen drop during menses, pregnancy, or perimenopause.
• Sleep disturbances – irregular patterns or sleep apnea.
• Stress and emotional strain – acute or chronic stress can precipitate clusters of attacks.
• Dietary triggers – caffeine excess, aged cheese, alcohol, MSG, or nitrates.
• Comorbid conditions – depression, anxiety, hypertension, or obesity increase migraine burden.

Diagnosis

There is no single laboratory test for migraine; diagnosis is clinical, based on the International Classification of Headache Disorders (ICHD‑3) criteria, supplemented by targeted investigations to rule out secondary causes.

Step‑by‑step diagnostic approach

1. Detailed History
   • Onset age, frequency, duration, and pattern of attacks.
   • Character of pain, associated symptoms, and aura.
   • Medication use, triggers, and impact on daily life.
2. Physical & Neurologic Examination – typically normal in primary migraine; focal deficits suggest secondary headache.
3. Headache Diary – at least 4 weeks of recorded attacks helps identify waxing/waning trends and trigger patterns.
4. Imaging (when indicated)
   • MRI brain with and without contrast – to exclude mass lesions, vascular malformations, or demyelinating disease.
   • CT head – urgent if sudden “thunderclap” headache, neurologic change, or trauma.
5. Laboratory Tests (selective)
   • CBC, ESR/CRP if inflammatory or infectious cause suspected.
   • Thyroid panel when hypothyroidism/ hyperthyroidism are plausible triggers.
6. Specialized Tests – In refractory cases, CGRP levels, neuropsychological testing, or sleep studies may be ordered.

Treatment Options

Treatment aims to abort acute attacks, prevent future episodes, and break the cycle of waxing and waning. A multimodal plan is often required.

Acute (Abortive) Therapies

• Triptans (sumatriptan, rizatriptan, eletriptan, etc.) – serotonin 5‑HT<sub>1B/1D</sub> agonists; most effective when taken early (<1 hour of onset).<sup>[2] Mayo Clinic, 2024</sup>
• NSAIDs (ibuprofen, naproxen) – reduce prostaglandin‑mediated inflammation; useful for mild‑moderate attacks.
• Combination analgesics (e.g., acetaminophen + aspirin + caffeine) – can be effective for patients who cannot tolerate triptans.
• Dihydroergotamine (DHE) – IV, nasal spray or injection; reserved for refractory attacks.
• Anti‑nausea agents (metoclopramide, prochlorperazine) – improve gastric emptying and enhance absorption of oral meds.
• CGRP receptor antagonists (gepants) – ubrogepant, rimegepant; effective for patients with cardiovascular risk where triptans are contraindicated.<sup>[3] Cleveland Clinic, 2023</sup>

Preventive (Prophylactic) Therapies

Consider when migraine is frequent (>4 days/month), disabling, or when medications are overused.

• Beta‑blockers (propranolol, metoprolol) – first‑line, especially with comorbid hypertension.
• Antidepressants (amitriptyline, venlafaxine) – useful when anxiety/depression coexist.
• Anticonvulsants (topiramate, valproic acid, gabapentin) – reduce cortical excitability.
• CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) – target the CGRP pathway; administered subcutaneously or intravenously every 1–3 months.<sup>[4] NIH, 2022</sup>
• Onabotulinumtoxin A – 31 injections across 7 head‑and‑neck muscles every 12 weeks; FDA‑approved for chronic migraine.
• Neuromodulation devices – single‑pulse transcranial magnetic stimulation (sTMS) or external trigeminal nerve stimulation for both acute and preventive use.

Lifestyle and Non‑pharmacologic Strategies

• Trigger identification & avoidance – keep a diary, limit caffeine, regular meals.
• Sleep hygiene – 7–9 hours/night, consistent schedule.
• Stress management – progressive muscle relaxation, biofeedback, mindfulness‑based stress reduction.
• Regular aerobic exercise – 30 minutes, 3–5 times/week improves vascular health.
• Hydration – aim for ≥2 L water/day.
• Dietary supplementation – magnesium (400 mg/day), riboflavin (400 mg/day), coenzyme Q10 (100 mg/day) have modest evidence for prophylaxis.<sup>[5] Cochrane Review, 2021</sup>

Living with Waxing and Waning Migraines

Managing day‑to‑day life involves anticipating fluctuations and having a flexible plan.

Practical Tips

1. Maintain a “rescue kit” – keep triptan, anti‑emetic, and an NSAID in a purse, at work, and in the car.
2. Schedule “quiet periods” during expected high‑frequency phases (e.g., menstrual weeks) – limit screen time, dim lights, and avoid loud environments.
3. Use a digital headache diary app – many allow automatic medication reminders and trend analysis.
4. Plan for work/school – discuss accommodations like flexible deadlines or a private, dark room.
5. Stay physically active – even light walking can reduce attack severity when done regularly.
6. Mind your mental health – depression and anxiety are common; consider counseling or CBT.
7. Monitor medication use – limit acute meds to ≤10 days/month to avoid medication‑overuse headache.

Prevention

Prevention focuses on reducing the frequency of the “waxing” peaks.

• Early preventive therapy – initiate prophylaxis when attacks become >4 days/month or when disability scores (e.g., MIDAS) rise.
• Hormonal modulation – for menstrual migraine, continuous combined oral contraceptives or perimenstrual estradiol supplementation can blunt the cyclic rise.
• Limit acute medication overuse – educate patients on maximum allowable doses; consider a structured withdrawal program if overuse has occurred.
• Regular follow‑up – every 3 months initially, then spaced based on stability.
• Vaccinations and health maintenance – control hypertension, diabetes, and sleep apnea, as these comorbidities can aggravate migraine.

Complications

If the waxing‑and‑waning pattern continues unchecked, several complications may arise:

• Medication‑overuse headache (MOH) – chronic daily headache due to frequent analgesic use.
• Chronic migraine – transition from episodic to ≥15 headache days/month, associated with reduced quality of life.
• Psychiatric comorbidity – higher rates of depression, anxiety, and suicidal ideation.
• Reduced productivity – missed workdays, impaired academic performance, and increased healthcare costs.
• Social isolation – avoidance of social activities due to fear of attacks.
• Progressive sensory sensitization – development of allodynia and persistent neck pain.

When to Seek Emergency Care

---

References:
[1] World Health Organization. Global Health Estimates 2023.
[2] Mayo Clinic. Migraine treatment: Options and side effects. Updated 2024.
[3] Cleveland Clinic. Gepants for acute migraine therapy. 2023.
[4] National Institutes of Health. CGRP monoclonal antibodies for migraine prophylaxis. 2022.
[5] Cochrane Database of Systematic Reviews. Magnesium, riboflavin, and CoQ10 for migraine prevention. 2021.

```